HSIAO JANE PH D
Known title: Vice Chairman & CTOCIK: 0001188834
HSIAO JANE PH D's purchase track record
How the stock did after each of HSIAO JANE PH D's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 10, 2023
Stock higher 6 months later
100%
3 months: 67%
Median 6-month return
+41.6%
3 months: +26.3%
Beat the S&P 500
67%
median +23.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/17/2024 | OPK | $143K | +26.3% | +43.4% | +17.9% |
| 1/5/2024 | OPK | $131K | +51.7% | +41.6% | +18.5% |
| 11/10/2023 | OPK | $127K | -16.7% | +1.6% | +18.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| OPK | ▲ Buy | Grant | 500,000 | $0 | 7/24/2024 | View on chart |
| OPK | ▲ Buy | Open Market | 150,000 | $143K | 1/17/2024 | View on chart |
| OPK | ▲ Buy | Open Market | 150,010 | $131K | 1/5/2024 | View on chart |
| OPK | ▲ Buy | Open Market | 34,058 | $43K | 11/10/2023 | View on chart |
| OPK | ▲ Buy | Open Market | 65,942 | $84K | 11/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
OPKO Health Shares Rise on $722M BioReference Asset Sale
OPKO Health announced it sold BioReference laboratory assets to Labcorp for $722 million, a key part of Labcorp’s up to $872 million acquisition. The transaction was reflected in a sharp increase in OPKO’s stock price. The deal highlights OPKO’s focus on divesting non‑core assets. The move follows Labcorp’s broader strategy to expand its laboratory services.
OPKO Health Shares Rise on $722M BioReference Asset Sale. OPKO Health announced it sold BioReference laboratory assets to Labcorp for $722 million, a key part of Labcorp’s up to $872 million acquisition. The transaction was reflected in a sharp increase in OPKO’s stock price. The deal highlights OPKO’s focus on divesting non‑core assets. The move follows Labcorp’s broader strategy to expand its laboratory services.